Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer

Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer

Bibliographic Details
Main Authors:	Aman Chaudhary, Ajay Gogia
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Cancer Research, Statistics, and Treatment
Online Access:	http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=796;epage=797;aulast=Chaudhary

Similar Items

Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
by: Moulid Hidayat, et al.
Published: (2019-11-01)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
by: Melissa Bersanelli, et al.
Published: (2014-09-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
by: Yuta Nio, et al.
Published: (2022-11-01)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
by: Yali Yi, et al.
Published: (2022-06-01)

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
by: Koichi Goto, et al.
Published: (2023-03-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
by: Adèle L’Hostis, et al.
Published: (2023-07-01)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
by: Yahua Wu, et al.
Published: (2023-12-01)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
by: Jing Wang, et al.
Published: (2023-08-01)

Diffuse Lung Metastases in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Subba R. Digumarthy, et al.
Published: (2019-09-01)

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
by: Mari Tone, et al.
Published: (2023-05-01)

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
by: Antonio Rossi, et al.
Published: (2022-12-01)

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
by: Aakash Desai, et al.
Published: (2024-02-01)

Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
by: Dylan A. Farnsworth, et al.
Published: (2021-12-01)

Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer
by: Yueqin Wang, et al.
Published: (2023-05-01)

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
by: Bi-Cheng Wang, et al.
Published: (2022-01-01)

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials
by: Bi-Cheng Wang, et al.
Published: (2022-01-01)

Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line
by: Bereczky Biborka, et al.
Published: (2008-05-01)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024-02-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
by: Woraseth Saifon, et al.
Published: (2022-09-01)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
by: Dan Yan, et al.
Published: (2021-11-01)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
by: Dan Yan, et al.
Published: (2022-08-01)

Application of Immune Checkpoint Inhibitors in EGFR Mutant  Advanced Non-small Cell Lung Cancer
by: Yujun ZHENG, et al.
Published: (2022-09-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer
by: Hsien-Neng Huang, et al.
Published: (2024-01-01)

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
by: Lavinia Tan, et al.
Published: (2024-02-01)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
by: Nathaniel Wiest, et al.
Published: (2021-11-01)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
by: Ajaz Bulbul, et al.
Published: (2018-04-01)

Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
by: Jianghua Ding, et al.
Published: (2023-06-01)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
by: Carolien Eggermont, et al.
Published: (2022-07-01)

COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER
by: S. A. Protsenko, et al.
Published: (2017-01-01)

An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report
by: Gabriela Chowaniecova, et al.
Published: (2022-12-01)

Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization
by: Julia Schueler, et al.
Published: (2019-07-01)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023-03-01)